Abstract
The objective of the current study was to investigate whether minocycline improves the effect of an existing multiple sclerosis (MS) medication, interferon-beta, on experimental autoimmune encephalomyelitis (EAE) in mice. When used at sub-optimal doses, neither medication affected EAE but their combination at these doses led to the significant alleviation of EAE disease severity scores and histological outcomes. In culture, the toxicity of T cells to neurons was alleviated by their prior exposure to minocycline or interferon-beta and their combination further attenuated neuronal death. Collectively, these results suggest the utility of the combination of minocycline and interferon-beta in MS.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Animals
-
Cell Death / immunology
-
Cell Proliferation / drug effects
-
Cells, Cultured
-
Coculture Techniques
-
Cytotoxicity, Immunologic
-
Disease Models, Animal
-
Drug Therapy, Combination
-
Encephalomyelitis, Autoimmune, Experimental / drug therapy*
-
Encephalomyelitis, Autoimmune, Experimental / immunology*
-
Encephalomyelitis, Autoimmune, Experimental / pathology
-
Humans
-
Interferon Type I / administration & dosage
-
Interferon Type I / pharmacology
-
Interferon Type I / therapeutic use*
-
Lymphocyte Activation / drug effects
-
Lymphocyte Activation / immunology
-
Mice
-
Minocycline / administration & dosage
-
Minocycline / pharmacology
-
Minocycline / therapeutic use*
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / immunology*
-
Multiple Sclerosis / pathology
-
Neurons / drug effects
-
Neurons / immunology
-
Neurons / pathology
-
Recombinant Proteins
-
Severity of Illness Index
-
T-Lymphocyte Subsets / cytology
-
T-Lymphocyte Subsets / drug effects
-
T-Lymphocyte Subsets / immunology
Substances
-
Interferon Type I
-
Recombinant Proteins
-
Minocycline